Drug intelligence / Profile preview

WD-910

Development stage: Phase 1
Lead developer: Zhejiang Wenda Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

WD-910 is a small molecule drug that acts as a TYK2 (Tyrosine-protein kinase 2) inhibitor. It is being developed by Ningbo Wenda Pharmaceutical Technology Co., Ltd. The drug is currently in Phase 1 clinical trials, with potential therapeutic applications for multiple sclerosis, dementia, and Parkinson's disease. TYK2 inhibition is a mechanism that may help modulate immune responses in various inflammatory and neurological conditions.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on WD-910.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-910.

Explore the full profile